News articles about ICU Medical (NASDAQ:ICUI) have been trending somewhat positive recently, Accern reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. ICU Medical earned a daily sentiment score of 0.07 on Accern’s scale. Accern also assigned media coverage about the medical instruments supplier an impact score of 46.4091422933139 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the headlines that may have effected Accern Sentiment’s rankings:

ICU Medical (ICUI) opened at 164.90 on Friday. The stock has a market capitalization of $3.27 billion, a PE ratio of 66.04 and a beta of 0.37. The firm has a 50-day moving average price of $172.11 and a 200-day moving average price of $158.73. ICU Medical has a 52 week low of $120.15 and a 52 week high of $176.50.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Wednesday, August 9th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.58 by $0.06. ICU Medical had a return on equity of 7.56% and a net margin of 6.10%. The firm had revenue of $331.51 million during the quarter, compared to analyst estimates of $318.30 million. During the same quarter in the previous year, the firm posted $1.15 earnings per share. The company’s quarterly revenue was up 242.8% on a year-over-year basis. Equities research analysts predict that ICU Medical will post $4.14 EPS for the current fiscal year.

A number of equities analysts have commented on ICUI shares. Gabelli reaffirmed a “buy” rating on shares of ICU Medical in a research note on Friday. Zacks Investment Research raised ICU Medical from a “hold” rating to a “buy” rating and set a $193.00 price target on the stock in a research note on Thursday, July 20th. Roth Capital cut ICU Medical from a “buy” rating to a “neutral” rating in a research note on Thursday, May 11th. They noted that the move was a valuation call. BidaskClub raised ICU Medical from a “hold” rating to a “buy” rating in a research note on Saturday, June 17th. Finally, Sidoti cut ICU Medical from a “buy” rating to a “neutral” rating in a research note on Tuesday, June 20th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. ICU Medical currently has an average rating of “Hold” and an average target price of $193.00.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact ICU Medical (ICUI) Share Price” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-icu-medical-icui-share-price/1478569.html.

In other news, Director Joseph R. Saucedo sold 4,500 shares of the business’s stock in a transaction that occurred on Tuesday, May 16th. The stock was sold at an average price of $162.51, for a total transaction of $731,295.00. Following the transaction, the director now directly owns 3,091 shares in the company, valued at approximately $502,318.41. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Chairman Vivek Jain sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 11th. The stock was sold at an average price of $170.80, for a total value of $17,080,000.00. Following the transaction, the chairman now owns 110,925 shares in the company, valued at $18,945,990. The disclosure for this sale can be found here. Over the last quarter, insiders sold 227,349 shares of company stock worth $38,623,370. 15.90% of the stock is currently owned by insiders.

ICU Medical Company Profile

ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.

Insider Buying and Selling by Quarter for ICU Medical (NASDAQ:ICUI)

Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.